## **Supplementary Material**

## How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements

Wiesner Agnieszka<sup>1</sup>, Paśko Paweł<sup>1</sup> and Kujawska Małgorzata<sup>2,\*</sup>

<sup>&</sup>lt;sup>1</sup>Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Str, 30-688 Kraków, Poland; <sup>2</sup>Department of Toxicology, Poznan University of Medical Sciences, 30 Dojazd Str., 60-631 Poznań, Poland



### **PRISMA 2020 for Abstracts Checklist**

Section and Topic	Item #	Checklist item	Reported (Yes/No)			
TITLE						
Title	1	Identify the report as a systematic review.	Yes			
BACKGROUND	-					
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Yes			
METHODS	_					
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	No (specified in the main text)			
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	No (specified in the main text)			
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	Not applicable (only qualitative synthesis)			
Synthesis of results	6	Specify the methods used to present and synthesise results.	Not applicable (only qualitative synthesis)			
RESULTS	-					
Included studies	7	Give the <b>total number of included studies</b> and participants and summarise relevant characteristics of studies.	Yes			
Synthesis of results	8	Present <b>results for main outcomes</b> , preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Yes			
DISCUSSION						
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Yes			
Interpretation	10	Provide a general interpretation of the results and important implications.	Yes			
OTHER						
Funding	11	Specify the primary source of funding for the review.	No (no funding)			
Registration	12	Provide the register name and registration number.	No (study not registered)			

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71



# PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE	- "		
Title	1	Identify the report as a systematic review.	Title: How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? – <b>A Systematic Review</b> of Drugs Interactions with Food and Dietary Supplements
ABSTRACT	-		
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	See Abstracts checklist.
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	In the "Introduction" section, all paragraphs except the last
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	In the "Introduction" section, last paragraph
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	In the "Inclusion criteria" and "Exclusion Criteria" sections
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	In the "Search strategy" section, first paragraph
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	In the "Search strategy" section, second paragraph
			In the "Inclusion criteria" section ("We made no restrictions for study year, study design, number of participants, or their characteristics")
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	In the "Search strategy" section, first paragraph
			In the "Authors' contributions" section
Data collection	9	Specify the methods used to collect data from reports, including how many reviewers collected	In the "Data extraction" section, first paragraph
process		data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	In the "Authors' contributions" section
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	In the "Inclusion criteria" section ("All articles describing or assessing the impact of meals, beverages, and dietary supplements on the pharmacokinetic and pharmacodynamic parameters")
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	In the "Data extraction" section
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
Synthesis	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g.	Not applicable – our study is only qualitative, we did not



# PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
methods		tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	perform quantitative synthesis
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	In Figure 1. Flowchart of the searching strategy
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	In Figure 1. Flowchart of the searching strategy In the "Eligible studies" section
Study characteristics	17	Cite each included study and present its characteristics.	In Table 1, Table 2, Table 3, and Table 4
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for	Not applicable – our study is only qualitative, we did not



#### **PRISMA 2020 Checklist**

Section and Topic	Item #	Checklist item	Location where item is reported
		each synthesis assessed.	perform quantitative synthesis
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Not applicable – our study is only qualitative, we did not perform quantitative synthesis
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	In the "Results and discussion" section (except subsections: "Eligible studies", "Level of evidence", and "Studies limitations")
	23b	Discuss any limitations of the evidence included in the review.	In the "Studies limitations" section
			In the "Level of evidence" section
	23c	Discuss any limitations of the review processes used.	In the "Studies limitations" section
	23d	Discuss implications of the results for practice, policy, and future research.	In the "Conclusion" section
OTHER INFORMA	TION		
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	The review was not registered
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	The protocol was not prepared
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Not applicable
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	In the "Funding" section
Competing interests	26	Declare any competing interests of review authors.	In the "Conflict of interest" section
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Data extracted from included studies – reported in Table 1, Table 2, Table 3, and Table 4 The remaining – not applicable

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <a href="http://www.prisma-statement.org/">http://www.prisma-statement.org/</a>